| 16206603
|
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)]. |
Ter Arkh |
2005 |
Skvortsov AA;Nasonova SN;Sychev AV;Arbolishvili GN;Baklanova NA;Mareev VIu;Belenkov IuN |
View
More |
| 16883264
|
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study]. |
Kardiologiia |
2006 |
Skvortsov AA;Nasonova SN;Sychev AV;Orlova IaA;Baklanova NA;Masenko VP;Mareev VIu;Belenkov IuN |
View
More |
| 18347439
|
Heart rate variability in white-coat hypertension. |
Blood Press Monit |
2008 |
Madsen LB;Rasmussen JK;Moller DS;Nyvad O;Pedersen EB |
View
More |
| 7568983
|
[The influence of opioid receptor blockade on the behavior of selected biochemical and hormonal parameters in patients with renovascular hypertension studied under water immersion conditions]. |
Przegl Lek |
1995 |
Baczynski R;Kokot F |
View
More |
